<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065061</url>
  </required_header>
  <id_info>
    <org_study_id>CS15049</org_study_id>
    <nct_id>NCT04065061</nct_id>
  </id_info>
  <brief_title>Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations</brief_title>
  <official_title>Investigation of Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grape King Bio Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed as randomized double blind placebo study to investigate the efficacy
      of Erinacine A-enriched Hericium erinaceus mycelia for improvement of recognition, vision,
      and functional MRI alterations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were recruited with diagnosis of mild or medium dementia, according to criteria by
      NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and
      Stroke-Alzheimer's Disease and Related Disorders Association) as probable or possible
      Alzheimer's disease. Upon signature of informed consent, they were subject to: (1) Cognitive
      assessments, including Mini-Mental State Examination(MMSE), Neuropsychiatric Inventory (NPI),
      Cognitive Abilities Screening Instrument (CASI), and Instrumental Activities of Daily Living
      (IADL) on weeks 0, 12, 24, and 49, (2) Blood Markers Tests, including DHEAS, Alpha
      1-antichymotrypsin, Superoxide Dismutase, and Homocysteine, Apolipoprotein E, Hemoglobin,
      Calcium, Albumin, and Amyloid Beta on weeks 0, 24, and 49, (3) fMRI Assessments for
      Super-resolution Track Density Imaging (TDI), and Blood Oxygenation Level-Dependent (BOLD)
      Signal Mapping, on weeks 0 and 49, (4) Vision Assessments, including Visual Acuity (VA) and
      Contrast Sensitivity (CS), on weeks 0, 24, and 49. Mann-Whitney U test and Wilcoxon tests
      were applied to examine the data before and after dietary intake of Erinacine A-enriched
      Hericium Erinaceus Mycelia after 49 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2015</start_date>
  <completion_date type="Actual">May 10, 2017</completion_date>
  <primary_completion_date type="Actual">May 10, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Double Blinded placebo study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>to be completed</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mini-Mental State Examination(MMSE)</measure>
    <time_frame>weeks 0,12, 24, and 49</time_frame>
    <description>Assess changes of Mini-Mental State Examination(MMSE) on weeks 0, 12, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>weeks 0,12, 24, and 49</time_frame>
    <description>Assess changes of Neuropsychiatric Inventory (NPI) on weeks 0, 12, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Abilities Screening Instrument (CASI)</measure>
    <time_frame>weeks 0,12, 24, and 49</time_frame>
    <description>Assess changes of Cognitive Abilities Screening Instrument (CASI) on weeks 0, 12, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Instrumental Activities of Daily Living (IADL)</measure>
    <time_frame>weeks 0,12, 24, and 49</time_frame>
    <description>Assess changes of Instrumental Activities of Daily Living (IADL) on weeks 0, 12, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dehydroepiandrosterone sulfate (DHEAS)</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of DHEAS on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha 1-antichymotrypsin</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Alpha 1-antichymotrypsinon weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superoxide Dismutase</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Superoxide Dismutase on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Homocysteine</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Homocysteine on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apolipoprotein E</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Apolipoprotein E on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Hemoglobin on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Calcium on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Albumin on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amyloid Beta</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Amyloid Beta on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI-Super-resolution Track Density Imaging (TDI)</measure>
    <time_frame>weeks 0 and 49</time_frame>
    <description>Assess changes of Super-resolution Track Density Imaging (TDI) on weeks 0 and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI-Blood Oxygenation Level-Dependent (BOLD) Signal Mapping</measure>
    <time_frame>weeks 0 and 49</time_frame>
    <description>Assess changes of Blood Oxygenation Level-Dependent (BOLD) Signal Mapping, on weeks 0 and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision Assessments-Visual Acuity (VA)</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Visual Acuity (VA) on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision Assessments-Contrast Sensitivity (CS)</measure>
    <time_frame>weeks 0, 24, and 49</time_frame>
    <description>Assess changes of Contrast Sensitivity (CS) on weeks 0, 24, and 49.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Supplement</condition>
  <condition>Cognition Disorders in Old Age</condition>
  <condition>Vision</condition>
  <condition>fMRI</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erinacine A-enriched Hericium Erinaceus Mycelia dietary supplement from week 0 to week 49.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dietary supplement from week 0 to week 49.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Erinacine A-enriched Hericium Erinaceus Mycelia</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplement was given to the participants.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 50 and 90

          -  Confirmed diagnosis of mild and intermediate Alzheimer's disease based on clinical
             assessments according to criteria of NINCDS-ADRDA (National Institute of Neurological
             and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders
             Association)

        Exclusion Criteria:

          -  vulnerable to injuries

          -  loss of self-recognition,

          -  loss of behavioral capacity

          -  with critical illness

          -  with major diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Pei-Cheng Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>David Pei-Cheng Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Erinacine A, supplement, Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

